Research Article
Glucocorticoid Withdrawal Symptoms and Quality of Life in Patients with Systemic Lupus Erythematosus
Table 4
Multivariate linear regression analyses identified the independent factor associated with SLEQoL.
| |||||||||||||||||||||||||||||||||
¶Adjusting for age, SLE duration, GCS dose, cSLEDAI-2K, SDI, used immunosuppressive agent. §Adjusting for , , treatment with GCS/immunosuppressive agent. was analysed with SLEQOL except mood domain. SLE: systemic lupus erythematosus; SLEQoL: systemic lupus erythematosus quality of life; FACIT: functional assessment of chronic illness therapy; PHQ-9: patient health questionnaire; PSQI: Pittsburgh’s sleep quality index; CI: confidence interval; GCS: glucocorticoids; cSLEDAI-2K: SLE Disease Activity Index 2000 (clinical domain); SDI: Systemic Lupus International Collaborating Clinic/American College of Rheumatology Damage Index. indicates moderate-severe depressive symptom; indicates poor sleeper. |